molecular docking, drug likeness studies and admet prediction of flavonoids as platelet-activating factor (paf) receptor binding

molecular docking, drug likeness studies and admet prediction of flavonoids as platelet-activating factor (paf) receptor binding

studies and scientific research indicate that the platelet-activating factor (paf) is a major pro-inflammatory mediator in the initiation and development of cancer. there is also evidence confirming that paf is an integral part of suppressing the immune system and promoting the appearance of a malignant tumor. for this reason, it is useful to analyze the molecular docking data of eleven flavonoids derivatives isolated from the active leaf extracted from chromolaena odorata with their anti-paf activity.

as a result, it is evident that the natural product of flavonoids may have a positive effect in the development of both therapeutic and preventive agents for platelet activating factor (paf) antagonist and suggests potential guidelines for the design of paf inhibitors. based on the docking score analysis, drug likeness study, and admet prediction. we found that six compounds respect all drug-likeness rules and can be used as a potent molecule for inhibition of platelet activating factor (paf).